The US Food and Drug Administration granted its first emergency use authorization for an OTC at-home molecular diagnostic test to Cue Health Inc. after investing $481m in the San Diego firm in 2020.
On 5 March, the FDA said it gave marketing authorization to Cue Health’s at-home molecular nucleic acid amplification test (NAAT) capable of detecting genetic material from the SARS-CoV-2 virus
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?